The Patent Finder

Medipost Co., Ltd.

15 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6
Ending by 2030
Mar 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Nov 21 to 26, 2026 · next Nov 21
  • 1 fee due Dec 4, 2026
    The maintenance fee for Pharmaceutical composition for the prevention or treatment of a pulmonary disorder comprising mesenchymal stem cells having improved proliferation and differentiation capacity (US 10,307,442) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,655,778SISP-1, a Novel P53 Target Gene and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 9,498,497Method of treating lung diseases using cells separated or proliferated from umbilical cord blood
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,439,931Administering umbilical cord blood-derived mesenchymal stem cells to treat nerve injury
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,238,692Composition Comprising a Culture Solution of Mesenchymal Stem Cells for the Treatment of Neural Diseases
In force
 · High confidence
In forceHigh confidence
US 9,387,226Neural cell proliferation induced through the culture of neural cells with umbilical cord blood-derived mesenchymal stem cells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,408,892Treating cartilage defect with UCB-MSC expressing TSP-2
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,614,191Use of ICAM-1 for prevention or treatment of neurological diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,040,298Method of selecting stem cells having high chondrogenic differentiation capability
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,580,687Method for culturing mesenchymal stem cells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,294,456Method for culturing mesenchymal stem cells
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 15 patents shown.
Pro members see all 15.
Pro members: see all 15 patents
Also on record, not counted in the 15: 1 lapsed for an unpaid fee · 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 11 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited